Kinase News and Research

RSS

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Scientists inhibit tumor formation

By studying mice with skin cancer, researchers at the Huntsman Cancer Institute at the University of Utah discovered a way to inhibit a mutant gene found in up to 30 percent of human tumors.

9 May 2005

Penn researchers demonstrate that a metabolic enzyme works through the tumor-suppressor protein p53 to control cellular replication

Researchers at the University of Pennsylvania School of Medicine have identified in normal cells that a common metabolic enzyme, which acts as a rheostat of cellular conditions, also controls cell replication.

4 May 2005

Mutated gene causes serious heart disease in newborns

The research group of professor Manfred Kilimann at the Department of Cell and Molecular Biology has elucidated the genetic cause of a severe heart disease in newborn children. This result will be published in the June issue of the American Journal of Human Genetics this week.

3 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Researchers have successfully induced adult heart-muscle cells to divide and multiply

In the best documented effort to date, researchers from the Howard Hughes Medical Institute at Children's Hospital Boston and Harvard Medical School have successfully induced adult heart-muscle cells to divide and multiply.

3 May 2005

FDA to change regulations regarding side-effect information in drug ads

The Food and Drug Administration is about to make it easier for you to understand both the benefits and risks of a prescription medication, it was revealed at the Second Annual Medical Liaison Seminar sponsored here by Scientific Advantage LLC.

2 May 2005

Researchers show protein's role in stopping bacterial-induced inflammation

In findings that could have implications for autoimmune disorders and drug-resistant bacterial infections, researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key protein involved in the appropriate shut-down of inflammation following an immune response to invading pathogens.

28 Apr 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

First time video capture of chemical signals that traverse human cells messaging

Researchers at UCSD and UC Irvine have captured on video for the first time chemical signals that traverse human cells in response to tiny mechanical jabs, like waves spreading from pebbles tossed into a pond. The scientists released the videos and technical details that explain how the visualization effect was created as part of a paper published in the April 21 issue of Nature.

21 Apr 2005

Breast cancer gene may play a major role in the recurrence of prostate cancer

A gene associated with breast cancer also may play a major role in the recurrence of prostate cancer, according to new research from the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Comprehensive Cancer Center.

20 Apr 2005

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers at Fox Chase Cancer Center in Philadelphia have identified a subset of ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif.

20 Apr 2005

New era drug gives hope to Gleevec resistant leukaemia sufferers

Gleevec, a drug regarded by many as having "wonder drug" capabilities in the treatment of chronic myelogenous leukaemia (CML) and other cancers, has been revealed as having shortcomings in that some patients have undergone a relapse after building a resistance to the drug. For others with the advanced stage of the disease, the drug has failed to produce durable remissions.

19 Apr 2005

Clinical trial of gefitinib for advanced lung cancer closes early

Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with non-small cell lung cancer (NSCLC) that had spread only to nearby tissues or lymph nodes. Review of interim data indicated that gefitinib would not improve survival.

19 Apr 2005

Australian researchers develop safer and more effective aspirin

Monash University researchers and staff of the Melbourne-based biotechnology company Cerylid Biosciences Ltd, have discovered and developed a new class of anti-clotting drugs that appears to be more effective than aspirin at preventing disease-causing blood clots and has fewer side effects.

19 Apr 2005

New findings about insulin-signaling in the liver could prove useful in understanding type 2 diabetes

A collaborative effort led by The Burnham Institute's Gen-Sheng Feng has created a mouse with improved glucose tolerance and insulin activity in the liver, and generated new findings about insulin-signaling in the liver that could prove useful in understanding the pathogenesis of type 2 diabetes.

12 Apr 2005

Assessing the function of unknown genes is feasible and can be done with a microarray phenotype

Microarrays provide a method of quantifying the expression and order of genes in a particular genome -- acting as a surrogate measure of cell physiology, said researchers at Baylor College of Medicine in a report that appears online today in the journal Nature Genetics.

10 Apr 2005

Discovery could lead to new drug targets for heart disease

Mice with glowing green hearts have yielded the latest clue in the search for molecules involved in structural heart disease. Vanderbilt University Medical Center investigators found that blocking the activity of a single protein, called CaM kinase, in the mouse heart protects against the damaging effects of a heart attack.

30 Mar 2005

A circadian rhythm gene discovered

A few rare people who consistently nod off early, then wake up wide-eyed much before dawn, can blame a newly-found mutant gene for their sleep troubles, Howard Hughes Medical Institute researchers announced today.

30 Mar 2005

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Identifying the genetic malfunction that causes these disorders raises the hope that researchers may be able to devise a targeted therapy, just as they have done for chronic myelogenous leukemia (CML), which is presently treated with Gleevec. The three leukemias that share a common genetic cause are polycythemia vera (PV), essential thrombocythemia (ET) and myeloid metaplasia with myelofibrosis (MMM).

28 Mar 2005

Kinase News and Research

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Scientists inhibit tumor formation

Penn researchers demonstrate that a metabolic enzyme works through the tumor-suppressor protein p53 to control cellular replication

Mutated gene causes serious heart disease in newborns

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Researchers have successfully induced adult heart-muscle cells to divide and multiply

FDA to change regulations regarding side-effect information in drug ads

Researchers show protein's role in stopping bacterial-induced inflammation

National clinical trial examines new option for kidney cancer patients

First time video capture of chemical signals that traverse human cells messaging

Breast cancer gene may play a major role in the recurrence of prostate cancer

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

New era drug gives hope to Gleevec resistant leukaemia sufferers

Clinical trial of gefitinib for advanced lung cancer closes early

Australian researchers develop safer and more effective aspirin

New findings about insulin-signaling in the liver could prove useful in understanding type 2 diabetes

Assessing the function of unknown genes is feasible and can be done with a microarray phenotype

Discovery could lead to new drug targets for heart disease

A circadian rhythm gene discovered

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News